News

Deal Announcements

Agios Pharmaceuticals Nets $33 Million First Round

Tuesday, July 8, 2008 5:46:00 AM PDT | VentureDeal Staff
Boston, Massachusetts -- Biopharmaceutical company Agios Pharmaceuticals has raised $33 million in its first venture capital funding round, according to a report in PE Hub.

Agios is developing treatments for cancer focused on regulating cancer cell metabolism.  It's research is increasing understanding of how cancer cells become addicted to utilizing more nutrients than normal cells.

Third Rock Ventures, Flagship Ventures and Arch Venture Partners invested the round.  Proceeds purposes were not disclosed by the company.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1